ultragenyx pharmaceutical inc  product pipeline review    compare about us  contact us home research category publisher list custom research cart compare research category user guide policies contact us about us site map home  market research report  pharmaceutical  pharmaceutical companies  pharma info market research report ultragenyx pharmaceutical inc  product pipeline review   published by global markets direct product code  published november   content info  pages price usd  pdf by email single user license usd  pdf by email site license usd  pdf by email global license ultragenyx pharmaceutical inc  product pipeline review   published november   content info  pages description summary global markets directs ultragenyx pharmaceutical inc  product pipeline review   provides an overview of the ultragenyx pharmaceutical incs pharmaceutical research and development focus this report provides comprehensive information on the current therapeutic developmental pipeline of ultragenyx pharmaceutical incs complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projects global markets directs report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets directs proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets directs team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis the report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass products note certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease scope the report provides brief overview of ultragenyx pharmaceutical inc including business description key information and facts and its locations and subsidiaries the report reviews current pipeline of ultragenyx pharmaceutical incs human therapeutic division and enlists all their major and minor projects the report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestones special feature on outlicensed and partnered product portfolio the report summarizes all the dormant and discontinued pipeline projects latest company statement latest news and deals relating to the ultragenyx pharmaceutical incs pipeline products reasons to buy evaluate ultragenyx pharmaceutical incs strategic position with total access to detailed information on its product pipeline assess the growth potential of ultragenyx pharmaceutical inc in its therapy areas of focus identify new drug targets and therapeutic classes in the ultragenyx pharmaceutical incs rd portfolio and develop key strategic initiatives to reinforce pipeline in those areas exploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gaps develop strategic initiatives by understanding the focus areas of ultragenyx pharmaceutical inc and exploit collaboration and partnership opportunities identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage plan mergers and acquisitions effectively by identifying the most promising pipeline of ultragenyx pharmaceutical inc develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope explore the dormant and discontinued projects of ultragenyx pharmaceutical inc and identify potential opportunities in those areas avoid intellectual property rights related issues table of contents product code gmdhccdbtable of contents table of contents list of tables list of figures ultragenyx pharmaceutical inc snapshot ultragenyx pharmaceutical inc overview key information key facts ultragenyx pharmaceutical inc  research and development overview key therapeutic areas ultragenyx pharmaceutical inc  pipeline review pipeline products by stage of development pipeline products  monotherapy pipeline products  partnered products partnered productscombination treatment modalities ultragenyx pharmaceutical inc  pipeline products glance ultragenyx pharmaceutical inc  late stage pipeline products preregistration productscombination treatment modalities phase iii productscombination treatment modalities ultragenyx pharmaceutical inc  clinical stage pipeline products phase ii productscombination treatment modalities ultragenyx pharmaceutical inc  early stage pipeline products preclinical productscombination treatment modalities ultragenyx pharmaceutical inc  drug profiles aceneuramic acid product description mechanism of action rd progress ux product description mechanism of action rd progress ux product description mechanism of action rd progress ux product description mechanism of action rd progress ultragenyx pharmaceutical inc  pipeline analysis ultragenyx pharmaceutical inc  pipeline products by target ultragenyx pharmaceutical inc  pipeline products by route of administration ultragenyx pharmaceutical inc  pipeline products by molecule type ultragenyx pharmaceutical inc  pipeline products by mechanism of action ultragenyx pharmaceutical inc  recent pipeline updates ultragenyx pharmaceutical inc  dormant projects ultragenyx pharmaceutical inc  locations and subsidiaries head office appendix methodology coverage secondary research primary research expert panel validation contact us disclaimer list of tables ultragenyx pharmaceutical inc key information ultragenyx pharmaceutical inc key facts ultragenyx pharmaceutical inc  pipeline by indication  ultragenyx pharmaceutical inc  pipeline by stage of development  ultragenyx pharmaceutical inc  monotherapy products in pipeline  ultragenyx pharmaceutical inc  partnered products in pipeline  ultragenyx pharmaceutical inc  partnered products combination treatment modalities  ultragenyx pharmaceutical inc  preregistration  ultragenyx pharmaceutical inc  phase iii  ultragenyx pharmaceutical inc  phase ii  ultragenyx pharmaceutical inc  preclinical  ultragenyx pharmaceutical inc  pipeline by target  ultragenyx pharmaceutical inc  pipeline by route of administration  ultragenyx pharmaceutical inc  pipeline by molecule type  ultragenyx pharmaceutical inc  pipeline products by mechanism of action  ultragenyx pharmaceutical inc  recent pipeline updates  ultragenyx pharmaceutical inc  dormant developmental projects list of figures ultragenyx pharmaceutical inc  pipeline by top  indication  ultragenyx pharmaceutical inc  pipeline by stage of development  ultragenyx pharmaceutical inc  monotherapy products in pipeline  ultragenyx pharmaceutical inc  partnered products in pipeline  ultragenyx pharmaceutical inc  pipeline by top  target  ultragenyx pharmaceutical inc  pipeline by top  route of administration  ultragenyx pharmaceutical inc  pipeline by top  molecule type  ultragenyx pharmaceutical inc  pipeline products by top  mechanism of action  phone intl  tollfreeus  europe  asia  new for   gii now purchases any market research reports from any publishers for you with noextra cost contact us for more details faq delivery time user license payment options compare multiple reports about contact user guide policies site map  copyright  global information inc all rights reserved ultragenyx  laboratory in southeast novato foursquarelog insign upnearbyget inspiredtop pickstrendingfoodcoffeenightlifefunshoppingultragenyxlaboratorysoutheast novato novatosavesharetipsultragenyxno tips and reviewslog in to leave a tip herepostno tips yetwrite a short note about what you liked what to order or other helpful advice for visitors photorelated searchesultragenyx novato  ultragenyx novato photos  ultragenyx novato location  ultragenyx novato address  ultragenyx novato  ultragenyx novato  ultragenyx southeast novato novatoaboutblogbusinessescitiesdevelopershelpjobscookies updatedprivacy updatedtermsenglishenglish français deutsch bahasa indonesia italiano  한국어 português русский español ภาษาไทย türkçe citiesatlantaaustinbostonchicagodallasdenverhoustonlas vegaslos angelesnew yorkphiladelphiaportlandsan diegosan franciscoseattlewashington dccountriesbelgiumbrazilcanadachilefinlandfrancegermanygreat britainhungaryindonesiajapanmexiconetherlandsphilippinesrussiasingaporespainthailandturkeymore great places in novatoabcdefghijklmnopqrstuvwxyzfoursquare    lovingly made in nyc  sfultragenyx leveroni ctnovato ca united statesget directions see moreunited states » marin county » novato » is this your business claim it nowmake sure your information is up to date plus use our free tools to find new customersyou must enable javascript to use foursquarecomwe use the latest and greatest technology available to provide the best possible web experienceplease enable javascript in your browser settings to continuedownload foursquare for your smart phone and start exploring the world around you ultragenyx pharmaceutical inc private company information  bloomberg july    pm et biotechnology company overview of ultragenyx pharmaceutical inc snapshot people company overview ultragenyx pharmaceutical inc a clinicalstage biopharmaceutical company focuses on the identification acquisition development and commercialization of various products for the treatment of rare and ultrarare genetic diseases in the united states the company is developing various biologics product candidates including krn a human monoclonal antibody that in phase iii adult study to bind and reduce the biological activity of fibroblast growth factor  to enhance abnormally low phosphate levels in patients with xlinked hypophosphatemia as well as for the treatment of tumorinduced osteomalacia its biologics product candidates also comprise recombinant human beta glucuronidase  ultragenyx pharmaceutical inc a clinicalstage biopharmaceutical company focuses on the identification acquisition development and commercialization of various products for the treatment of rare and ultrarare genetic diseases in the united states the company is developing various biologics product candidates including krn a human monoclonal antibody that in phase iii adult study to bind and reduce the biological activity of fibroblast growth factor  to enhance abnormally low phosphate levels in patients with xlinked hypophosphatemia as well as for the treatment of tumorinduced osteomalacia its biologics product candidates also comprise recombinant human beta glucuronidase rhgus an enzyme replacement therapy which completed the phase  clinical study for the treatment of mucopolysaccharidosis  and recombinant human protective protein cathepsina rhppca an enzyme replacement therapy which is in preclinical development for galactosialidosis the company is also developing range of smallmolecule product candidates such as ux a substrate replacement therapy that is in phase ii study for patients with fatty acid oxidation disorders as well as for patients with glucose transporter type deficiency syndrome and aceneuramic acid extendedrelease aceer an oral formulation of sialic acid which is in phase iii extension study to treat gne myopathy it has collaboration and license agreements with arcturus therapeutics inc takeda pharmaceutical company limited kyowa hakko kirin co ltd saint louis university baylor research institute nobelpharma co ltd alcami corporation hibm research group and st jude children’s research hospital the company was founded in  and is headquartered in novato california detailed description  leveroni courtnovato ca united statesfounded in  employees phone  wwwultragenyxcom key executives for ultragenyx pharmaceutical inc dr emil d kakkis md phd chief executive officer president and director age  total annual compensation k ms shalini sharp chief financial officer and executive vice president age  total annual compensation k dr jayson donald alexander dallas md chief commercial officer and executive vice president age  total annual compensation k mr john richard pinion ii chief quality operations officer and executive vice president of analytical sciences  research age  total annual compensation k ms karah herdman parschauer executive vice president and general counsel age  total annual compensation k compensation as of fiscal year  ultragenyx pharmaceutical inc key developments ultragenyx pharmaceutical inc reports unaudited financial results for the second quarter and six months ended june   jul   ultragenyx pharmaceutical inc reported unaudited financial results for the second quarter and six months ended june   for the quarter the company reported loss from operations of  compared to  a year ago loss before income taxes was  compared to  a year ago net loss was  or  per basic and diluted share compared to  or  per basic and diluted share a year ago for the six months the company reported loss from operations of  compared to  a year ago loss before income taxes was  compared to  a year ago net loss was  or  per basic and diluted share compared to  or  per basic and diluted share a year ago cash used in operations was  million compared to  million for the same period in  ultragenyx pharmaceutical inc q  earnings call jul   jul   ultragenyx pharmaceutical inc q  earnings call jul   ultragenyx provides regulatory update on burosumab jun   ultragenyx pharmaceutical inc announced that it has reached agreement with the fda at a prebiologics license application prebla meeting on the clinical package to support the burosumab krn bla filing for xlinked hypophosphatemia xlh at the meeting the fda agreed that the bla can be submitted based on available clinical data and confirmed that both pediatric and adult indications would be included in the review based on the agreement the submission of the burosumab bla is planned for the second half of  specifically for the pediatric xlh population the fda agreed that the  week data from study cl in  year olds and  week data from study cl in  year olds would be sufficient for review the fda confirmed that data from the pediatric phase  study cl would not be required for the bla filing to support the adult xlh indication the fda agreed that the review would be based on the totality of the data from the adult phase  study cl including fracture healing data fda would also accept some bone biopsy data from the  week open label bone quality phase  study in adults if available during the review as supportive evidence similar private companies by industry company name region n labs inc united states andme inc united states c tech corporation inc united states v biosciences inc united states bar biologics inc united states recent private companies transactions typedate target no transactions available in the past  months request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup most searched private companies company name geographic region lawyers committee for civil rights under law united states nyc inc united states the advertising council inc united states bertelsmann ag europe rush university united states sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact ultragenyx pharmaceutical inc please visit wwwultragenyxcom company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close ultragenyx pharmaceutical inc  product pipeline review   trends statistics segment and forecasts market size share analysis  market research store     gmt office hours  uscan toll free  us office no home categories become publisher news about us contact us select category consumer goods food  beverage heavy industry life sciences marketing  market research public sector service industries technology  media semiconductor chemical and materials metallurgical market research search home  life sciences  pharmaceuticals ultragenyx pharmaceutical inc  product pipeline review   published nov  format pdf  global markets direct  number of pages   code mrs   report details table of content inquiry for buying request sample ultragenyx pharmaceutical inc  product pipeline review   summary global markets direct’s ‘ultragenyx pharmaceutical inc  product pipeline review  ’ provides an overview of the ultragenyx pharmaceutical inc’s pharmaceutical research and development focus this report provides comprehensive information on the current therapeutic developmental pipeline of ultragenyx pharmaceutical inc’s complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projects global markets direct’s report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets direct’s proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets direct’s team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis the report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass products note certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease scope  the report provides brief overview of ultragenyx pharmaceutical inc including business description key information and facts and its locations and subsidiaries  the report reviews current pipeline of ultragenyx pharmaceutical inc’s human therapeutic division and enlists all their major and minor projects  the report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones  special feature on outlicensed and partnered product portfolio  the report summarizes all the dormant and discontinued pipeline projects  latest company statement  latest news and deals relating to the ultragenyx pharmaceutical inc’s pipeline products reasons to buy  evaluate ultragenyx pharmaceutical inc’s strategic position with total access to detailed information on its product pipeline  assess the growth potential of ultragenyx pharmaceutical inc in its therapy areas of focus  identify new drug targets and therapeutic classes in the ultragenyx pharmaceutical inc’s rd portfolio and develop key strategic initiatives to reinforce pipeline in those areas  exploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gaps  develop strategic initiatives by understanding the focus areas of ultragenyx pharmaceutical inc and exploit collaboration and partnership opportunities  identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage  plan mergers and acquisitions effectively by identifying the most promising pipeline of ultragenyx pharmaceutical inc  develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope  explore the dormant and discontinued projects of ultragenyx pharmaceutical inc and identify potential opportunities in those areas  avoid intellectual property rights related issues table of contents table of contents  list of tables  list of figures  ultragenyx pharmaceutical inc snapshot  ultragenyx pharmaceutical inc overview  key information  key facts  ultragenyx pharmaceutical inc  research and development overview  key therapeutic areas  ultragenyx pharmaceutical inc  pipeline review  pipeline products by stage of development  pipeline products  monotherapy  pipeline products  partnered products  partnered productscombination treatment modalities  ultragenyx pharmaceutical inc  pipeline products glance  ultragenyx pharmaceutical inc  late stage pipeline products  preregistration productscombination treatment modalities  phase iii productscombination treatment modalities  ultragenyx pharmaceutical inc  clinical stage pipeline products  phase ii productscombination treatment modalities  ultragenyx pharmaceutical inc  early stage pipeline products  preclinical productscombination treatment modalities  ultragenyx pharmaceutical inc  drug profiles  aceneuramic acid  product description  mechanism of action  rd progress  ux  product description  mechanism of action  rd progress  ux  product description  mechanism of action  rd progress  ux  product description  mechanism of action  rd progress  ultragenyx pharmaceutical inc  pipeline analysis  ultragenyx pharmaceutical inc  pipeline products by target  ultragenyx pharmaceutical inc  pipeline products by route of administration  ultragenyx pharmaceutical inc  pipeline products by molecule type  ultragenyx pharmaceutical inc  pipeline products by mechanism of action  ultragenyx pharmaceutical inc  recent pipeline updates  ultragenyx pharmaceutical inc  dormant projects  ultragenyx pharmaceutical inc  locations and subsidiaries  head office  appendix  methodology  coverage  secondary research  primary research  expert panel validation  contact us  disclaimer  list of tables ultragenyx pharmaceutical inc key information  ultragenyx pharmaceutical inc key facts  ultragenyx pharmaceutical inc  pipeline by indication   ultragenyx pharmaceutical inc  pipeline by stage of development   ultragenyx pharmaceutical inc  monotherapy products in pipeline   ultragenyx pharmaceutical inc  partnered products in pipeline   ultragenyx pharmaceutical inc  partnered products combination treatment modalities   ultragenyx pharmaceutical inc  preregistration   ultragenyx pharmaceutical inc  phase iii   ultragenyx pharmaceutical inc  phase ii   ultragenyx pharmaceutical inc  preclinical   ultragenyx pharmaceutical inc  pipeline by target   ultragenyx pharmaceutical inc  pipeline by route of administration   ultragenyx pharmaceutical inc  pipeline by molecule type   ultragenyx pharmaceutical inc  pipeline products by mechanism of action   ultragenyx pharmaceutical inc  recent pipeline updates   ultragenyx pharmaceutical inc  dormant developmental projects  list of figures ultragenyx pharmaceutical inc  pipeline by top  indication   ultragenyx pharmaceutical inc  pipeline by stage of development   ultragenyx pharmaceutical inc  monotherapy products in pipeline   ultragenyx pharmaceutical inc  partnered products in pipeline   ultragenyx pharmaceutical inc  pipeline by top  target   ultragenyx pharmaceutical inc  pipeline by top  route of administration   ultragenyx pharmaceutical inc  pipeline by top  molecule type   ultragenyx pharmaceutical inc  pipeline products by top  mechanism of action   inquiry for buying please fill your details below to inquire about this report  indicates required fields name email phone name of company titledesignation country name select country andorra united arab emirates afghanistan antigua and barbuda anguilla albania armenia angola antarctica argentina american samoa austria australia aruba åland islands azerbaijan bosnia and herzegovina barbados bangladesh belgium burkina faso bulgaria bahrain burundi benin saint barthélemy bermuda brunei darussalam bolivia plurinational state of bonaire sint eustatius and saba brazil bahamas bhutan bouvet island botswana belarus belize canada cocos keeling islands congo the democratic republic of the central african republic congo switzerland côte divoire cook islands chile cameroon china colombia costa rica cuba cape verde curaçao christmas island cyprus czech republic germany djibouti denmark dominica dominican republic algeria ecuador estonia egypt western sahara eritrea spain ethiopia finland fiji falkland islands malvinas micronesia federated states of faroe islands france gabon united kingdom grenada georgia french guiana guernsey ghana gibraltar greenland gambia guinea guadeloupe equatorial guinea greece south georgia and the south sandwich islands guatemala guam guineabissau guyana hong kong heard island and mcdonald islands honduras croatia haiti hungary indonesia ireland israel isle of man india british indian ocean territory iraq iran islamic republic of iceland italy jersey jamaica jordan japan kenya kyrgyzstan cambodia kiribati comoros saint kitts and nevis korea democratic peoples republic of korea republic of kuwait cayman islands kazakhstan lao peoples democratic republic lebanon saint lucia liechtenstein sri lanka liberia lesotho lithuania luxembourg latvia libya morocco monaco moldova republic of montenegro saint martin french part madagascar marshall islands macedonia the former yugoslav republic of mali myanmar mongolia macao northern mariana islands martinique mauritania montserrat malta mauritius maldives malawi mexico malaysia mozambique namibia new caledonia niger norfolk island nigeria nicaragua netherlands norway nepal nauru niue new zealand oman panama peru french polynesia papua new guinea philippines pakistan poland saint pierre and miquelon pitcairn puerto rico palestinian state of portugal palau paraguay qatar réunion romania serbia russian federation rwanda saudi arabia solomon islands seychelles sudan sweden singapore saint helena ascension and tristan da cunha slovenia svalbard and jan mayen slovakia sierra leone san marino senegal somalia suriname south sudan sao tome and principe el salvador sint maarten dutch part syrian arab republic swaziland turks and caicos islands chad french southern territories togo thailand tajikistan tokelau timorleste turkmenistan tunisia tonga turkey trinidad and tobago tuvalu taiwan province of china tanzania united republic of ukraine uganda united states minor outlying islands united states uruguay uzbekistan holy see vatican city state saint vincent and the grenadines venezuela bolivarian republic of virgin islands british virgin islands us viet nam vanuatu wallis and futuna samoa yemen mayotte south africa zambia zimbabwe how can we help you refresh captcha submit request sample please fill your details below to receive sample report  indicates required fields name email phone name of company titledesignation country name select country andorra united arab emirates afghanistan antigua and barbuda anguilla albania armenia angola antarctica argentina american samoa austria australia aruba åland islands azerbaijan bosnia and herzegovina barbados bangladesh belgium burkina faso bulgaria bahrain burundi benin saint barthélemy bermuda brunei darussalam bolivia plurinational state of bonaire sint eustatius and saba brazil bahamas bhutan bouvet island botswana belarus belize canada cocos keeling islands congo the democratic republic of the central african republic congo switzerland côte divoire cook islands chile cameroon china colombia costa rica cuba cape verde curaçao christmas island cyprus czech republic germany djibouti denmark dominica dominican republic algeria ecuador estonia egypt western sahara eritrea spain ethiopia finland fiji falkland islands malvinas micronesia federated states of faroe islands france gabon united kingdom grenada georgia french guiana guernsey ghana gibraltar greenland gambia guinea guadeloupe equatorial guinea greece south georgia and the south sandwich islands guatemala guam guineabissau guyana hong kong heard island and mcdonald islands honduras croatia haiti hungary indonesia ireland israel isle of man india british indian ocean territory iraq iran islamic republic of iceland italy jersey jamaica jordan japan kenya kyrgyzstan cambodia kiribati comoros saint kitts and nevis korea democratic peoples republic of korea republic of kuwait cayman islands kazakhstan lao peoples democratic republic lebanon saint lucia liechtenstein sri lanka liberia lesotho lithuania luxembourg latvia libya morocco monaco moldova republic of montenegro saint martin french part madagascar marshall islands macedonia the former yugoslav republic of mali myanmar mongolia macao northern mariana islands martinique mauritania montserrat malta mauritius maldives malawi mexico malaysia mozambique namibia new caledonia niger norfolk island nigeria nicaragua netherlands norway nepal nauru niue new zealand oman panama peru french polynesia papua new guinea philippines pakistan poland saint pierre and miquelon pitcairn puerto rico palestinian state of portugal palau paraguay qatar réunion romania serbia russian federation rwanda saudi arabia solomon islands seychelles sudan sweden singapore saint helena ascension and tristan da cunha slovenia svalbard and jan mayen slovakia sierra leone san marino senegal somalia suriname south sudan sao tome and principe el salvador sint maarten dutch part syrian arab republic swaziland turks and caicos islands chad french southern territories togo thailand tajikistan tokelau timorleste turkmenistan tunisia tonga turkey trinidad and tobago tuvalu taiwan province of china tanzania united republic of ukraine uganda united states minor outlying islands united states uruguay uzbekistan holy see vatican city state saint vincent and the grenadines venezuela bolivarian republic of virgin islands british virgin islands us viet nam vanuatu wallis and futuna samoa yemen mayotte south africa zambia zimbabwe how can we help you refresh captcha submit related reports global and europe bcg vaccine market  analysis and outlook to  jul  eu research  pages    code  mrs   this report presents a comprehensive overview of the bcg vaccine market in europe this shares the history data information from  to  and forecast from  to  this report provides a detailed analysis of the market its dynamics structure characteristics main players growth and demand drivers etc as a detailed analysis report it covers all details inside analysis and opinion in bcg vaccine industry this report focus global and europe market it covers details playe read more global onychomycosis tinea unguium drug detailed analysis report  jul  detailed analysis research  pages    code  mrs   this report splits onychomycosis tinea unguium drug by product drug form by product usage type this shares the history data information from  to  and forecast from  to  and this report mainly introduces volume and value market share by players by regions by product type by consumers and also their price change details as a detailed analysis report it covers all details inside analysis and opinion in onychomycosis tinea unguium drug industry this report fo read more life science analytics  global market outlook  jun  stratistics mrc  pages    code  mrs   according to stratistics mrc the global life science analytics market is expected to grow from  billion in  to reach  billion by  with a cagr of  some of the factors propelling the market growth are raising demand for analytics in sales and marketing applications increasing need of these solutions especially in clinical trials and improvements in technological advancements however lack of skilled professionals huge implementation costs and financial limitations read more chronic kidney disease ckd drugs  global market outlook  jul  stratistics mrc  pages    code  mrs   according to stratistics mrc the global chronic kidney disease ckd drugs market is expected to grow from  billion in  to reach  billion by  with a cagr of  drivers that are shaping the global market include growing incidences of chronic kidney diseases rise in aged population rising incidence of diabetes and obesity related disorders significant unmet requirements and beneficial reimbursement policies on the other hand factors such as intense competition fr read more acaricides  global market outlook  jul  stratistics mrc  pages    code  mrs   according to stratistics mrc the global acaricides market is expected to grow from  million in  to reach  million by  with a cagr of  high demand for meat dairy products and crops growth in crop protection industry and rise in productivity are some of the factors propelling the market growth however increase in cost alternative acaricides sources and regulatory restrictions are the factors suppressing the market on the other hand expansion of bioactive aca read more global and united states bacillus subtilis depth research report  jul  united states research  pages    code  mrs   this report mainly introduces volume and value market share by players by regions by product type by consumers and also their price change details as a depth research report it covers all details inside analysis and opinion in bacillus subtilis industry this report focus united states market it covers details players regions product type and other details as following major companies bayer germany basf germany tonglu huifeng china kernel biotech china w read more global bacterial vaginosis drug market rport  jun  bisreport  pages    code  mrs   global bacterial vaginosis drug market report  full report  multi license section  section price as below page  chart and figure  publisher bisreport delivery time  hour contact salesbisreportcom phone  with the slowdown in world economic growth the bacterial vaginosis drug industry has also suffered a certain impact but still maintained a relatively optimistic growth the past four years bacterial vaginosis drug market size to maintain read more global alzheimers disease drug market rport  jun  bisreport  pages    code  mrs   global alzheimer’s disease drug market report  full report  multi license section  section price as below page  chart and figure  publisher bisreport delivery time  hour contact salesbisreportcom phone  with the slowdown in world economic growth the alzheimer’s disease drug industry has also suffered a certain impact but still maintained a relatively optimistic growth the past four years alzheimer’s disease drug market size to maintain read more global protein powder detailed analysis report  jul  detailed analysis research  pages    code  mrs   this report mainly introduces volume and value market share by players by regions by product type by consumers and also their price change details as a detailed analysis report it covers all details inside analysis and opinion in protein powder industry this report splits protein powder market price size first speciality second speciality protein powder flavors which covers the history data information from  to  and forecast from  to  this report focus glob read more opioidinduced constipation oic  pipeline review h  jul  global markets direct  pages    code  mrs   opioidinduced constipation oic  pipeline review h  summary global markets directs latest pharmaceutical and healthcare disease pipeline guide opioidinduced constipation oic  pipeline review h  provides an overview of the opioidinduced constipation oic toxicology pipeline landscape opioids are effective pain relievers but often have the side effect of constipation these medicines affect the gastrointestinal tract in a variety of ways opioids increase the amo read more payment mode single user  usd multi user  usd corporate user  usd latest report  global nonslip epoxy glass flake paint market research report  global parking sensors market research report  global nitrogen oxide sensor market research report  global nuclear density gauge market research report  global automotive interior materials market research report view more latest news global chitosan market set for rapid growth to reach usd  billion by  zion market research has published a new report titled chitosan market for water treatment biomed development of ecommerce to reshape global mobile hotspot router market mobile hotspot is a popular feature on smart phones that provide wireless internet access on many global carotenoids market is expected to reach around usd  billion in  zion market research has published a new report titled carotenoids market by type astaxanthin be soaring demand from food  beverages industry to act as prime driving for ascorbic acid market reports zion market research ascorbic acid is extensively available in nature mostly rich in leafy vegetables and fresh fruits global energy management system ems market is set for a rapid growth and is expected to reach usd  million by  zion market research has published a new report titled energy management system market ems by so view more single user  usd view pricing find help how to order disclaimer faqs return policy sitemap our company about us terms and conditions privacy policy we accept the following payment methods     market research store  market research reports microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft product pipeline  rare disease drug development  ultragenyx pipeline ultragenyx is a clinicalstage biopharmaceutical company committed to bringing to market novel products for the treatment of rare and ultrarare diseases with a focus on serious debilitating genetic diseases founded in  the company has rapidly built a diverse portfolio of product candidates with the potential to address diseases for which the unmet medical need is high the biology for treatment is clear and for which there are no approved therapies biologic krnux xlinked hypophosphatemia xlh      tumorinduced osteomalacia tio      rhgusux mucopolysaccharidosis  mps       small molecule ux longchain fatty acid oxidation disorders faod      glucose transporter  deficiency glut ds      aceneuramic acidux gne myopathy gnem      pipeline krn for xlh krn for tio rhgus ux for faod ux for glut ds aceneuramic acid presentations  publications about management emil d kakkis md phd jayson dallas md dennis huang thomas kassberg karah parschauer john pinion shalini sharp board of directors daniel g welch emil d kakkis md phd william aliski deborah dunsire md lars ekman md phd matthew k fust michael narachi clay b siegall phd grants  charitable contributions message from bio pipeline krn for xlh krn for tio rhgus ux for faod ux for glut ds aceneuramic acid presentations  publications for patients xlh tio mps  lcfaod glut ds gne myopathy access to investigational therapies investors press releases events  presentations corporate governance management board of directors committee composition sec filings stock information analyst coverage investor faq contact us careers benefits summer internships job opportunities partnering current partnerships contact driving directions about management emil d kakkis md phd jayson dallas md dennis huang thomas kassberg karah parschauer john pinion shalini sharp board of directors daniel g welch emil d kakkis md phd william aliski deborah dunsire md lars ekman md phd matthew k fust michael narachi clay b siegall phd grants  charitable contributions message from bio pipeline krn for xlh krn for tio rhgus ux for faod ux for glut ds aceneuramic acid presentations  publications for patients xlh tio mps  lcfaod glut ds gne myopathy access to investigational therapies investors press releases events  presentations corporate governance management board of directors committee composition sec filings stock information analyst coverage investor faq contact us careers benefits summer internships job opportunities partnering current partnerships contact driving directions privacy policy   ultragenyx pharmaceuticalwebsite design hane chow inc privacy policy rare genetic diseases  ultragenyx transforming good science into great medicine for rare genetic diseases deep and diversified product pipeline developing multiple clinicalstage programs in parallel                                   focused on serious rare and ultrarare diseases working with patients and medical professionals to treat rare diseases dedicated to creating new treatments  join a highperformance team focused on rare diseases jul   ultragenyx reports second quarter  financial results and corporate update jul   ultragenyx to host conference call for second quarter  financial results and corporate update jun   ultragenyx provides regulatory update on burosumab krn about management emil d kakkis md phd jayson dallas md dennis huang thomas kassberg karah parschauer john pinion shalini sharp board of directors daniel g welch emil d kakkis md phd william aliski deborah dunsire md lars ekman md phd matthew k fust michael narachi clay b siegall phd grants  charitable contributions message from bio pipeline krn for xlh krn for tio rhgus ux for faod ux for glut ds aceneuramic acid presentations  publications for patients xlh tio mps  lcfaod glut ds gne myopathy access to investigational therapies investors press releases events  presentations corporate governance management board of directors committee composition sec filings stock information analyst coverage investor faq contact us careers benefits summer internships job opportunities partnering current partnerships contact driving directions about management emil d kakkis md phd jayson dallas md dennis huang thomas kassberg karah parschauer john pinion shalini sharp board of directors daniel g welch emil d kakkis md phd william aliski deborah dunsire md lars ekman md phd matthew k fust michael narachi clay b siegall phd grants  charitable contributions message from bio pipeline krn for xlh krn for tio rhgus ux for faod ux for glut ds aceneuramic acid presentations  publications for patients xlh tio mps  lcfaod glut ds gne myopathy access to investigational therapies investors press releases events  presentations corporate governance management board of directors committee composition sec filings stock information analyst coverage investor faq contact us careers benefits summer internships job opportunities partnering current partnerships contact driving directions   ultragenyx pharmaceuticalwebsite design hane chow inc privacy policy contact  ultragenyx  rare disease drug development   leveroni court novato california san francisco bay area contact ultragenyx pharmaceutical inc headquarters  leveroni court novato ca  phone  fax   email infoultragenyxcom   contact driving directions about management emil d kakkis md phd jayson dallas md dennis huang thomas kassberg karah parschauer john pinion shalini sharp board of directors daniel g welch emil d kakkis md phd william aliski deborah dunsire md lars ekman md phd matthew k fust michael narachi clay b siegall phd grants  charitable contributions message from bio pipeline krn for xlh krn for tio rhgus ux for faod ux for glut ds aceneuramic acid presentations  publications for patients xlh tio mps  lcfaod glut ds gne myopathy access to investigational therapies investors press releases events  presentations corporate governance management board of directors committee composition sec filings stock information analyst coverage investor faq contact us careers benefits summer internships job opportunities partnering current partnerships contact driving directions about management emil d kakkis md phd jayson dallas md dennis huang thomas kassberg karah parschauer john pinion shalini sharp board of directors daniel g welch emil d kakkis md phd william aliski deborah dunsire md lars ekman md phd matthew k fust michael narachi clay b siegall phd grants  charitable contributions message from bio pipeline krn for xlh krn for tio rhgus ux for faod ux for glut ds aceneuramic acid presentations  publications for patients xlh tio mps  lcfaod glut ds gne myopathy access to investigational therapies investors press releases events  presentations corporate governance management board of directors committee composition sec filings stock information analyst coverage investor faq contact us careers benefits summer internships job opportunities partnering current partnerships contact driving directions privacy policy   ultragenyx pharmaceuticalwebsite design hane chow inc privacy policy rare disease drug development  ultragenyx about ultragenyx is a clinicalstage biopharmaceutical company committed to bringing to market novel products for the treatment of rare and ultrarare diseases with a focus on serious debilitating genetic diseases founded in  the company has rapidly built a diverse portfolio of product candidates with the potential to address diseases for which the unmet medical need is high the biology for treatment is clear and for which there are no approved therapies the company is led by a management team experienced in the development and commercialization of rare disease therapeutics ultragenyxs strategy is predicated upon time and costefficient drug development with the goal of delivering safe and effective therapies to patients with the utmost urgency about management emil d kakkis md phd jayson dallas md dennis huang thomas kassberg karah parschauer john pinion shalini sharp board of directors daniel g welch emil d kakkis md phd william aliski deborah dunsire md lars ekman md phd matthew k fust michael narachi clay b siegall phd grants  charitable contributions message from bio about management emil d kakkis md phd jayson dallas md dennis huang thomas kassberg karah parschauer john pinion shalini sharp board of directors daniel g welch emil d kakkis md phd william aliski deborah dunsire md lars ekman md phd matthew k fust michael narachi clay b siegall phd grants  charitable contributions message from bio pipeline krn for xlh krn for tio rhgus ux for faod ux for glut ds aceneuramic acid presentations  publications for patients xlh tio mps  lcfaod glut ds gne myopathy access to investigational therapies investors press releases events  presentations corporate governance management board of directors committee composition sec filings stock information analyst coverage investor faq contact us careers benefits summer internships job opportunities partnering current partnerships contact driving directions about management emil d kakkis md phd jayson dallas md dennis huang thomas kassberg karah parschauer john pinion shalini sharp board of directors daniel g welch emil d kakkis md phd william aliski deborah dunsire md lars ekman md phd matthew k fust michael narachi clay b siegall phd grants  charitable contributions message from bio pipeline krn for xlh krn for tio rhgus ux for faod ux for glut ds aceneuramic acid presentations  publications for patients xlh tio mps  lcfaod glut ds gne myopathy access to investigational therapies investors press releases events  presentations corporate governance management board of directors committee composition sec filings stock information analyst coverage investor faq contact us careers benefits summer internships job opportunities partnering current partnerships contact driving directions privacy policy   ultragenyx pharmaceuticalwebsite design hane chow inc privacy policy rare genetic diseases  ultragenyx transforming good science into great medicine for rare genetic diseases deep and diversified product pipeline developing multiple clinicalstage programs in parallel                                   focused on serious rare and ultrarare diseases working with patients and medical professionals to treat rare diseases dedicated to creating new treatments  join a highperformance team focused on rare diseases jul   ultragenyx reports second quarter  financial results and corporate update jul   ultragenyx to host conference call for second quarter  financial results and corporate update jun   ultragenyx provides regulatory update on burosumab krn about management emil d kakkis md phd jayson dallas md dennis huang thomas kassberg karah parschauer john pinion shalini sharp board of directors daniel g welch emil d kakkis md phd william aliski deborah dunsire md lars ekman md phd matthew k fust michael narachi clay b siegall phd grants  charitable contributions message from bio pipeline krn for xlh krn for tio rhgus ux for faod ux for glut ds aceneuramic acid presentations  publications for patients xlh tio mps  lcfaod glut ds gne myopathy access to investigational therapies investors press releases events  presentations corporate governance management board of directors committee composition sec filings stock information analyst coverage investor faq contact us careers benefits summer internships job opportunities partnering current partnerships contact driving directions about management emil d kakkis md phd jayson dallas md dennis huang thomas kassberg karah parschauer john pinion shalini sharp board of directors daniel g welch emil d kakkis md phd william aliski deborah dunsire md lars ekman md phd matthew k fust michael narachi clay b siegall phd grants  charitable contributions message from bio pipeline krn for xlh krn for tio rhgus ux for faod ux for glut ds aceneuramic acid presentations  publications for patients xlh tio mps  lcfaod glut ds gne myopathy access to investigational therapies investors press releases events  presentations corporate governance management board of directors committee composition sec filings stock information analyst coverage investor faq contact us careers benefits summer internships job opportunities partnering current partnerships contact driving directions   ultragenyx pharmaceuticalwebsite design hane chow inc privacy policy careers  rare disease drug development and commercialization  ultragenyx careers ultragenyx is committed to creating and maintaining an environment that values hard work fosters creativity and promotes success we have a professional work environment fueled by the talent and expertise of our employees and driven by our commitment to treating patients with significant unmet medical needs  we have a strong commitment to diversity to fair and equitable treatment of our valued employees and to fostering internal and external interactions and decisions that reflect an organization known for its integrity at the same time we have set very high standards for employees to sustain our growth and achievement we expect dedication to our company’s mission and performance with the highest level of quality and integrity ultragenyx is growing and  looking for highly motivated individuals who share our goal and committment of developing treatments for rare and ultrarare disease for patients with unmet medical needs if you are looking for a meaningful position that has the ability to impact patients and be part of a high performance team focused on the same goal this is the opportunity you have been waiting for our company culture statement is clear and simple – and so ‘us’ to be a hero for our patients at ultragenyx being a hero means embodying a set of core attributes that define who we are and what we stand for generous we are committed to helping  sharing our knowledge and skills with our patients our field and each other courageous we go where others won’t  targeting untreated diseases and taking on the challenges that move our field forward relentless we won’t give up fighting for our patients  together always searching for solutions dynamic we learn and adapt  constantly searching for deeper understanding and rapidly evolving our plans based on our insights possibility we seek the undiscovered discoveries  we’re committed to finding options for those who don’t have any careers benefits summer internships job opportunities about management emil d kakkis md phd jayson dallas md dennis huang thomas kassberg karah parschauer john pinion shalini sharp board of directors daniel g welch emil d kakkis md phd william aliski deborah dunsire md lars ekman md phd matthew k fust michael narachi clay b siegall phd grants  charitable contributions message from bio pipeline krn for xlh krn for tio rhgus ux for faod ux for glut ds aceneuramic acid presentations  publications for patients xlh tio mps  lcfaod glut ds gne myopathy access to investigational therapies investors press releases events  presentations corporate governance management board of directors committee composition sec filings stock information analyst coverage investor faq contact us careers benefits summer internships job opportunities partnering current partnerships contact driving directions about management emil d kakkis md phd jayson dallas md dennis huang thomas kassberg karah parschauer john pinion shalini sharp board of directors daniel g welch emil d kakkis md phd william aliski deborah dunsire md lars ekman md phd matthew k fust michael narachi clay b siegall phd grants  charitable contributions message from bio pipeline krn for xlh krn for tio rhgus ux for faod ux for glut ds aceneuramic acid presentations  publications for patients xlh tio mps  lcfaod glut ds gne myopathy access to investigational therapies investors press releases events  presentations corporate governance management board of directors committee composition sec filings stock information analyst coverage investor faq contact us careers benefits summer internships job opportunities partnering current partnerships contact driving directions privacy policy   ultragenyx pharmaceuticalwebsite design hane chow inc privacy policy management  ultragenyx pharmaceutical inc management show all emil d kakkis md phd chief executive officer and president dr kakkis is currently ultragenyx’s president and chief executive officer he is also president of the nonprofit everylife foundation for rare diseases an organization he founded in  to work on regulatory policy issues  over the last  years dr kakkis is best known for his work developing novel treatments for rare disorders he began his work developing an enzyme replacement therapy aldurazyme® for the rare disorder mps i with minimal funding and support the struggle to get the therapy translated from a successful canine model to patients succeeded due to the critical financial support of the ryan foundation a patient organization formed by mark and jeanne dant for their son ryan aldurazyme development was later supported by biomarin and genzyme leading to fda approval in  after joining biomarin in  dr kakkis guided the development and approval of two more treatments for rare disorders mps vi and pku and has contributed to the initiation of  other treatment programs for rare disorders three of which are now in clinical development or approved after  years at biomarin dr kakkis funded and launched the everylife foundation for rare diseases a nonprofit foundation dedicated to the acceleration of biotech innovation for rare diseases through practical and scientifically sound improvements to development strategies regulatory policy and law the foundation successfully advocated for improvements to the accelerated approval pathway for rare disease treatments that was passed by congress in fdasia in  dr kakkis went on to found ultragenyx in  to focus on developing as many rare and ultrarare disease therapeutics as possible since its founding ultragenyx has grown to more than  employees developing treatments for five rare and ultrarare diseases in phase  and phase  clinical development   the company went public in january  rare  nasdaq dr kakkis is board certified in both pediatrics and medical genetics he graduated from pomona college magna cum laude and received the vaile prize for his research  he received combined md and phd degrees from the ucla medical scientist program and received the bogen prize for his research he completed a pediatrics residency and medical genetics training fellowship at harbor ucla medical center from  and from  to  was an assistant professor of pediatrics at harborucla medical center where he initiated the enzyme therapy program for mps i  thomas kassberg chief business officer and senior vice president mr kassberg joined ultragenyx in november  he is responsible for leading the companys business development and corporate strategic planning activities as well as the human resources and legal affairs functions mr kassberg brings more than twenty years of experience in the pharmaceutical and biotechnology industries prior to joining ultragenyx mr kassberg worked as an independent consultant in corporate development and business strategy and consulted with a number of companies including corium international inc and ribx pharmaceuticals inc before becoming a consultant mr kassberg worked at proteolix inc where he served as executive vice president of corporate development overseeing business development corporate strategic planning and legal affairs prior to proteolix mr kassberg served as senior vice president of corporate development and commercial operations at intermune inc at intermune he oversaw the commercial team responsible for inline sales of actimmune® and prelaunch planning for latestage products mr kassberg was also a cofounder of plexxikon where he served as vice president business and corporate development in this role he helped to establish the companys initial operations in addition to leading the companys corporate development activities prior to plexxikon mr kassberg served as the senior director of business development and corporate licensing at sugen until the companys acquisition by pharmacia mr kassberg began his career at bristolmyers squibb where he held a variety of positions in strategic planning managed care sales and financial and product analysis he holds an mba from northwestern university and a ba in economics and management from gustavus adolphus college shalini sharp chief financial officer and senior vice president ms sharp joined ultragenyx in may  as chief financial officer and senior vice president she is a member of the senior management team and is responsible for leading the corporate finance function including strategic financial planning accounting budgeting and forecasting financial analysis general risk analysis and financing activities ms sharp is a member of the board of directors of agenus inc formerly antigenics inc a publicly traded biotechnology firm where she served as chief financial officer from  to  she joined agenus in  and held increasing roles of responsibility spanning strategic planning corporate development investor relations corporate finance and business development prior to agenus ms sharp held similar roles at elan pharmaceuticals from  to  including serving as chief of staff to the chairman of the board of directors during that companys restructing with  years of industry experience ms sharp has spearheaded numerous financing and business development transactions that have been critical to the success of agenus and elan  prior to elan ms sharp was a management consultant at mckinsey  company as well as an investment banker at goldman sachs specializing in pharmaceuticals and medical devices ms sharp holds both a ba magna cum laude and mba from harvard university sunil agarwal md chief medical officer and senior vice president sunil agarwal md joined ultragenyx as chief medical officer in august  prior to ultragenyx dr agarwal served in various leadership capacities at genentech for  years most recently he held the position of senior vice president and global head of clinical development for omni ophthalmology metabolism neurosciences immunology and infectious diseases since january  prior to that dr agarwal held the positions of senior vp for immunology and infectious diseases and vp for rheumatology from july  to december  he also held the position of vp of genentech drug safety from january  to july  from september  to january  dr agarwal held positions of increasing responsibility in genentech’s immunology clinical organization and was involved in the development oversight of multiple molecules including raptiva rituxan and ocrelizumab before joining genentech dr agarwal was at medimmune and guilford pharmaceuticals where he worked in both development and medical affairs and led the formation of the medical affairs organization for guilford dr agarwal obtained his bachelor of science in neurobiology at cornell university and then earned his medical degree from tufts university school of medicine he completed his residency at children’s national medical center cnmc washington dc and subsequently joined the facility at george washington university school of medicine as an assistant clinical professor of pediatrics he practiced in the pediatric emergency department at cnmc dennis huang chief technical operations officer and senior vice president dennis huang joined ultragenyx in may  he will be responsible for the short and long term strategy and development plans for manufacturing and supply chain distribution of all ultragenyx products from inception to commercialization as well as manage all aspects of clinical and commercial manufacturing operations and provide leadership and direction to the technical operations team    most recently dennis was the senior vice president of manufacturing and supply chain for intermune incorporated from  to  where he led the global manufacturing organization and supply chain activities for the company prior to intermune dennis served as the vice president of biologics manufacturing and development for allergan inc during his year tenure at allergan he improved the commercial manufacturing performance and expanded the biologics development capability which resulted in a rapid expansion of the biologics pipeline earlier in his career dennis held several positions at novartis ag formerly chiron inc at genentech inc and at synergen currently amgen where he worked in a number of roles including manufacturing quality and process development dennis holds a ba in chemistry from knox college in galesburg ilinois john ditton vice president commerical planning mr ditton brings over  years of senior management background in strategic marketing and new product planning with strong operational and sales knowledge developed as a leader of commercial teams in healthcare rare diseases pharmaceutical and medical device marketing he has led successful us and row orphan product launches in addition to serving in leadership roles with respect to marketing campaigns for largemarket pharmaceutical products mr ditton joined ultragenyx in april  and is responsible for commercial planning for pipeline products at the company mr ditton was most recently the chief operating officer at everylife foundation for rare diseases a position he held from  to  prior to everylife foundation he served as the vice president of marketing at diamics from  to  director of global marketing at biomarin pharmaceutical from  to  senior product manager at merckdey from  to  and business development manager at health plan of the redwoods from  to  cordelia leonard rac vice president regulatory affairs ms leonard heads up the company’s regulatory affairs department whose members collectively have over  years of regulatory experience working with the fda ema pmda and other worldwide regulatory agencies approximately twenty of those  years she and her team spent working to develop drugs for orphan indications at biomarin pharmaceutical during her  year tenure at biomarin ms leonard started up and led the cmc regulatory group then transferred to the clinicalnonclinical regulatory group where she advanced to lead that group as well she was involved in securing various global approvals for aldurazyme naglazyme kuvan and orapred opt prior to biomarin ms leonard worked in regulatory for  years at cerus corporation on drugdevice combination products in protein purification and analytical chemistry at boehringer mannheim and in carbohydrate chemistry at genentech ms leonard received bachelor degrees in chemistry and biological science from the university of california irvine and holds both us and eu regulatory affairs certifications vimal srivastava vice president program development with more than  years of project and portfolio management experience from research to commercialization stage programs mr srivastava joined ultragenyx in august  and serves as vice president program development overseeing the program development activities for the company mr srivastava’s experience and background includes over  years in the pharmaceutical and biotechnology industry specifically focused on drug development in neurosciences and metabolic disorders including rare genetic disorders before joining ultragenyx mr srivastava was senior director portfolio and project management at elanjanssen alzheimer immunotherapy a position he held from  until  he was also director global program manager diabetes at amgen from  to  and director program management at biomarin pharmaceutical from  to  mr srivastava holds a bs in pharmacy from banaras hindu university a ms in medicinal chemistry from st johns university and a mas in management from johns hopkins university michael vellard phd vice president research dr vellard joined ultragenyx as vice president research in may  prior to joining ultragenyx dr vellard worked as head of lysosomal biology at biomarin pharmaceutical inc a biopharmaceutical company from october  to may  he was a postdoctoral fellow in the pediatric department at ucla harbor medical center from september  to june  dr vellard received his bs in natural and life sciences and ms in molecular and cellular genetics from the university of lyon i france  he obtained his phd in virology from the  pasteur and curie institutes universities paris vi vii and xi france antonis koutsoukos phd vice president biometrics dr koutsoukos joined ultragenyx as our vice president of biometrics in october  he is responsible for leading the biostatistics statistical programming and data management functions for the company prior to ultragenyx mr koutsoukos worked as vice president of biometrics at allos therapeutics a biopharmaceutical company from september  to march  which was acquired by spectrum pharmaceuticals he was also director of biostatistics at amgen inc a biotechnology company from may  to september  prior to amgen mr koutsoukos spent  years at quintiles as a director of biostatistics his experience also includes  years at the fda center for drugs evaluation and research cder division and about  years at the national cancer institute biometric research branch ctep dct mr koutsoukos received his phd and ma both in mathematical statistics from the university of maryland college park javier san martin md vice president clinical development dr san martin has served as our vice president clinical development since december  prior to ultragenyx dr san martin served as senior vice president of clinical development at alder biopharmaceuticals inc a pharmaceutical company from january  through may  prior to alder dr san martin served as executive director and global development leader at amgen inc a biotechnology company from march  to september  prior to amgen dr san martin served as medical advisor at eli lilly and company a pharmaceutical company from june  to february  dr san martin received his md from the university of buenos aires medical school and completed his residence in internal medicine at cemic university of buenos aires investors press releases events  presentations corporate governance management board of directors committee composition sec filings stock information analyst coverage investor faq contact us shareholder tools briefcase email alerts print share facebook google linkedin twitter email rss about pipeline for patients investors careers partnering contact about pipeline for patients investors careers partnering contact   ultragenyx pharmaceuticals website design hane chow inc privacy policy bing places for business bing places for business sign in using your microsoft account work account google account facebook account dont have an account create one stock information  ultragenyx pharmaceutical inc stock information stock quote rare      pm et on jul   previous close  open  volume  exchange nasdaq day high  day low  week high  week low  stock chart compare benchmark nasdaq nyse sp  amex benchmark area graph ohlc line graph candlestick time intraday  day  month  month  months  year  years  years  years range update from to   the stock information provided is for informational purposes only and is not intended for trading purposes the stock information is provided by esignal stock charts are provided by edgar online both third party services and ultragenyx pharmaceutical inc does not maintain or provide information directly to this service stock information is delayed approximately  minutes sign up for email alerts the stock information provided is for informational purposes only and is not intended for trading purposes the stock information is provided by esignal stock charts are provided by nasdaq omx both third party services and ultragenyx pharmaceutical inc does not maintain or provide information directly to this service stock information is delayed approximately  minutes investors press releases events  presentations corporate governance management board of directors committee composition sec filings stock information analyst coverage investor faq contact us shareholder tools briefcase email alerts print share facebook google linkedin twitter email rss about pipeline for patients investors careers partnering contact about pipeline for patients investors careers partnering contact   ultragenyx pharmaceuticals website design hane chow inc privacy policy events  presentations  ultragenyx pharmaceutical inc events  presentations presentations date title jun   corporate presentation  mb add to briefcase file is in briefcase upcoming events details on upcoming events are not yet available please click here to be notified of all upcoming events archived events date details jul    pm et second quarter  financial results and corporate update listen to webcast jun    pm pt goldman sachs th annual global healthcare conference jun    pm et jefferies  global healthcare conference may    pm pt bank of america merrill lynch  healthcare conference may    pm et first quarter  financial results and corporate update apr    pm pt phase  data results for krn burosumab in adult xlh patients mar    am et barclays global healthcare conference mar    am et cowen and company th annual health care conference feb    pm et fourth quarter  financial results and corporate update feb    am et leerink partners th annual global healthcare conference jan    am pt th annual jp morgan healthcare conference sep    am et ultragenyx asbmr data conference call aug    pm et second quarter  financial results and corporate update jul    pm pt phase  data results for rhgus in mps  may    pm et first quarter  financial results and corporate update feb    pm et fourth quarter and full year  financial results and corporate update  add file to briefcase investors press releases events  presentations corporate governance management board of directors committee composition sec filings stock information analyst coverage investor faq contact us shareholder tools briefcase email alerts print share facebook google linkedin twitter email rss about pipeline for patients investors careers partnering contact about pipeline for patients investors careers partnering contact   ultragenyx pharmaceuticals website design hane chow inc privacy policy investors  ultragenyx pharmaceutical inc investors ultragenyx is a clinicalstage biopharmaceutical company committed to bringing to market novel products for the treatment of rare and ultrarare diseases with a focus on serious debilitating genetic diseases founded in  the company has rapidly built a diverse portfolio of product candidates with the potential to address diseases for which the unmet medical need is high the biology for treatment is clear and for which there are no approved therapies the company is led by a management team experienced in the development and commercialization of rare disease therapeutics ultragenyx’s strategy is predicated upon time and costefficient drug development with the goal of delivering safe and effective therapies to patients with the utmost urgency press releases jul   ultragenyx reports second quarter  financial results and corporate update jul   ultragenyx to host conference call for second quarter  financial results and corporate update jun   ultragenyx provides regulatory update on burosumab krn view all press releases » investors press releases events  presentations corporate governance management board of directors committee composition sec filings stock information analyst coverage investor faq contact us shareholder tools briefcase email alerts print share facebook google linkedin twitter email rss about pipeline for patients investors careers partnering contact about pipeline for patients investors careers partnering contact   ultragenyx pharmaceuticals website design hane chow inc privacy policy flashratings  principles facebook autocomplete demo post a rating  month price target   trending sign up log in flashratings principles  flashratings mission is to provide you  the investor  with as much honest and professional research on your investments as possible  we believe its much better to get a multitude of credible opinions on an investment than to arbitrarily follow any single advisor  be it your banker a friend or a tv pundit  flashratings does not provide advice our job is to accurately and objectively report on analysts credible research and opinions the only advice flashratings will ever give you is to absorb as much fundamental research and different opinions as possible and make your own decisions  flashratings favors covering analysts with proven track records but will cover all analysts as long as their research is honest and professional sign up » flashratings  contact us facebook autocomplete demo post a rating  month price target   trending sign up log in contact flashratings your emotional state excited confused worried upset panicked angry flashratings  about us facebook autocomplete demo post a rating  month price target   trending sign up log in flashratings  all research for my stocks the most comprehensive equity research coverage available online never miss a single piece of research upgrade downgrade or target price change by any analyst firm on any stock equity research by professional analysts  especially their rationales more than their forecasts  contains far more interesting and important information about the actual fundamentals of the traded companies than can be gathered from conventional news reports our mission is to unlock access to valuable research on stocks for all retail investors professionals institutions take advantage of our costeffective subscriptions to have flashratingss comprehensive realtime feed delivered into your intranet and trading floor platforms institutional subscriptions websites become a content licensing partner and display flashratingss popular news feed on your website content licensing advertisers advertise with us and have flashratings readers with attractive demographics take advantage of your products advertising facebook autocomplete demo post a rating  month price target   home trending sign up log in analyst ranking   name measured ratings sucess rate avg return  mizuho      credit suisse      jefferies      cantor fitzgerald      bank of america merrill lynch      jmp securities      goldman sachs      raymond james      fbr capital markets      william blair     ultragenyx pharmaceutical inc  product pipeline review   infowiseguyreportscom     chat with us           us         uk login register home report categories premium reports access to  premium reports aerospace  defense agri  food automotive basic materials consumer goods  retail energy life sciences manufacturing  construction services telecom  it education security  intelligence systems technology company reports report categories aerospace  defense agri  food automotive basic materials consumer goods  retail energy life sciences manufacturing  construction services telecom  it education security  intelligence systems technology company reports publisher knowledgestore countries browse by country browse by continent browse by group  region conferences upcoming conferences seminars conferences upcoming conferences seminars countries browse by country browse by continent browse by group  region news  blog press release blog news  blogs press release blogs faqs about us about our company our team life at wgr careers contact us there are no items currently in your basket there are no items currently in your basket search home all reports ultragenyx pharmaceutical inc  product pipeline review  ultragenyx pharmaceutical inc  product pipeline review   wgr  september  global  pages global markets direct description table of content sample report enquiry before buy related reports ultragenyx pharmaceutical inc  product pipeline review  summaryglobal markets direct’s ‘ultragenyx pharmaceutical inc  product pipeline review  ’ provides an overview of the ultragenyx pharmaceutical inc’s pharmaceutical research and development focusthis report provides comprehensive information on the current therapeutic developmental pipeline of ultragenyx pharmaceutical inc’s complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projectsglobal markets direct’s report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets direct’s proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets direct’s team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basisthe report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass productsnote certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated diseasescope the report provides brief overview of ultragenyx pharmaceutical inc including business description key information and facts and its locations and subsidiaries the report reviews current pipeline of ultragenyx pharmaceutical inc’s human therapeutic division and enlists all their major and minor projects the report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones  special feature on outlicensed and partnered product portfolio the report summarizes all the dormant and discontinued pipeline projects latest company statement  latest news and deals relating to the ultragenyx pharmaceutical inc’s pipeline productsreasons to buy evaluate ultragenyx pharmaceutical inc’s strategic position with total access to detailed information on its product pipeline assess the growth potential of ultragenyx pharmaceutical inc in its therapy areas of focus identify new drug targets and therapeutic classes in the ultragenyx pharmaceutical inc’s rd portfolio and develop key strategic initiatives to reinforce pipeline in those areas exploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gaps develop strategic initiatives by understanding the focus areas of ultragenyx pharmaceutical inc and exploit collaboration and partnership opportunities identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage plan mergers and acquisitions effectively by identifying the most promising pipeline of ultragenyx pharmaceutical inc develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope explore the dormant and discontinued projects of ultragenyx pharmaceutical inc and identify potential opportunities in those areas avoid intellectual property rights related issues table of contentstable of contents list of tables list of figures ultragenyx pharmaceutical inc snapshot ultragenyx pharmaceutical inc overview key information key facts ultragenyx pharmaceutical inc  research and development overview key therapeutic areas ultragenyx pharmaceutical inc  pipeline review pipeline products by stage of development pipeline products  monotherapy pipeline products  partnered products partnered productscombination treatment modalities ultragenyx pharmaceutical inc  pipeline products glance ultragenyx pharmaceutical inc  clinical stage pipeline products phase ii productscombination treatment modalities phase i productscombination treatment modalities ultragenyx pharmaceutical inc  early stage pipeline products preclinical productscombination treatment modalities ultragenyx pharmaceutical inc  drug profiles aceneuramic acid product description mechanism of action rd progress ux product description mechanism of action rd progress ux product description mechanism of action rd progress ux product description mechanism of action rd progress ux product description mechanism of action rd progress ultragenyx pharmaceutical inc  pipeline analysis ultragenyx pharmaceutical inc  pipeline products by target ultragenyx pharmaceutical inc  pipeline products by route of administration ultragenyx pharmaceutical inc  pipeline products by molecule type ultragenyx pharmaceutical inc  pipeline products by mechanism of action ultragenyx pharmaceutical inc  recent pipeline updates ultragenyx pharmaceutical inc  locations and subsidiaries head office appendix methodology coverage secondary research primary research expert panel validation contact us disclaimer list of tablesultragenyx pharmaceutical inc key information ultragenyx pharmaceutical inc key facts ultragenyx pharmaceutical inc  pipeline by indication  ultragenyx pharmaceutical inc  pipeline by stage of development  ultragenyx pharmaceutical inc  monotherapy products in pipeline  ultragenyx pharmaceutical inc  partnered products in pipeline  ultragenyx pharmaceutical inc  partnered products combination treatment modalities  ultragenyx pharmaceutical inc  phase ii  ultragenyx pharmaceutical inc  phase i  ultragenyx pharmaceutical inc  preclinical  ultragenyx pharmaceutical inc  pipeline by target  ultragenyx pharmaceutical inc  pipeline by route of administration  ultragenyx pharmaceutical inc  pipeline by molecule type  ultragenyx pharmaceutical inc  pipeline products by mechanism of action  ultragenyx pharmaceutical inc  recent pipeline updates  list of figuresultragenyx pharmaceutical inc  pipeline by top  indication  ultragenyx pharmaceutical inc  pipeline by stage of development  ultragenyx pharmaceutical inc  monotherapy products in pipeline  ultragenyx pharmaceutical inc  partnered products in pipeline  ultragenyx pharmaceutical inc  pipeline by top  target  ultragenyx pharmaceutical inc  pipeline by top  route of administration  ultragenyx pharmaceutical inc  pipeline by top  molecule type   request a sample report name email optional request you to please fill in your corporate emailid job title company phone no your country select country afghanistan albania algeria american samoa andorra angola anguilla antigua  barbuda argentina armenia aruba australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia  herzegovina botswana brazil brunei bulgaria burkina faso burundi cambodja cameroon canada cape verde cayman islands central african republic chad chile china colombia comoros congobrazzaville congokinshasa cook islands costa rica cote divoire croatia cuba cyprus czech republic denmark djibouti dominica dominican republic ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland malvinas faroes fiji finland france frenchguiana tahitifrench polinesia gabon gambia georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guinea guineabissau guyana haiti vatican city honduras hong kong hungary iceland india indonesia iran iraq ireland israel italy jamaica japan jordan kazakhstan kenya kiribati north korea south korea kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macao macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mexico micronesia moldova monaco mongolia montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles new caledonia new zealand nicaragua niger nigeria norfolk northern mariana norway oman pakistan palau panama papua new guinea paraguay peru philippines pitcairn poland portugal puerto rico qatar reunion romania russian federation rwanda saint helena saint lucia saint pierre and miquelon st vincent  the grenadines samoa san marino sao tome  principe saudi arabia senegal seychelles sierra leone singapore slovakia slovenia solomon islands somalia south africa spain sri lanka sudan suriname svalbard and jan mayen swaziland sweden switzerland syria taiwan tajikistan tanzania thailand togo tokelau tonga trinidad  tobago tunisia turkey turkmenistan turks and caicos islands tuvalu uganda ukraine united arab emirates united kingdom united states of america uruguay uzbekistan vanuatu venezuela viet nam virgin islands british virgin islands us wales western sahara yemen zambia zimbabwe timorleste curacao st kitts  nevis sint maarten guernsey isle of man jersey niue montenegro do you have any specific field of interest confirm make an enquiry before buying this report name email optional request you to please fill in your corporate emailid job title company phone no your country select country afghanistan albania algeria american samoa andorra angola anguilla antigua  barbuda argentina armenia aruba australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia  herzegovina botswana brazil brunei bulgaria burkina faso burundi cambodja cameroon canada cape verde cayman islands central african republic chad chile china colombia comoros congobrazzaville congokinshasa cook islands costa rica cote divoire croatia cuba cyprus czech republic denmark djibouti dominica dominican republic ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland malvinas faroes fiji finland france frenchguiana tahitifrench polinesia gabon gambia georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guinea guineabissau guyana haiti vatican city honduras hong kong hungary iceland india indonesia iran iraq ireland israel italy jamaica japan jordan kazakhstan kenya kiribati north korea south korea kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macao macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mexico micronesia moldova monaco mongolia montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles new caledonia new zealand nicaragua niger nigeria norfolk northern mariana norway oman pakistan palau panama papua new guinea paraguay peru philippines pitcairn poland portugal puerto rico qatar reunion romania russian federation rwanda saint helena saint lucia saint pierre and miquelon st vincent  the grenadines samoa san marino sao tome  principe saudi arabia senegal seychelles sierra leone singapore slovakia slovenia solomon islands somalia south africa spain sri lanka sudan suriname svalbard and jan mayen swaziland sweden switzerland syria taiwan tajikistan tanzania thailand togo tokelau tonga trinidad  tobago tunisia turkey turkmenistan turks and caicos islands tuvalu uganda ukraine united arab emirates united kingdom united states of america uruguay uzbekistan vanuatu venezuela viet nam virgin islands british virgin islands us wales western sahara yemen zambia zimbabwe timorleste curacao st kitts  nevis sint maarten guernsey isle of man jersey niue montenegro your enquiry confirm purchase this market research report usd gbp euro yen inr user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  add to cart buy now   email report   sample report   save page   any questions   download information   check discount   download order form   email report   sample report   save page   any questions   download information   check discount   download order form contact us akash anand domain head business development saleswiseguyreportscom     us     uk rishabh arora domain head business development saleswiseguyreportscom  abu koshy domain head business development saleswiseguyreportscom     related reports × tell a friend about this report your name your email friends name friends email your enquiry send ultragenyx pharmaceutical inc  stockboard signin  register × register or signin to get realtime alerts from this company july th at pm globenewswire inc ultragenyx reports second quarter  financial results and corporate update novato calif july   globe newswire  ultragenyx pharmaceutical inc nasdaqrare a biopharmaceutical company focused on the development of novel products for rare and ultrarare diseases today reported its financial results and corporate update for the quarter ended june   “we look forward to submitting our biologics license application bla for burosumab and working with the fda to bring this potential treatment to adult and pediatric patients” said emil d kakkis md phd chief executive officer and president of ultragenyx “we believe the first bone biopsy data from our ongoing phase  bone quality study underscore burosumab’s impact on the underlying bone disease in adults with xlh”  second quarter  financial results for the second quarter of  ultragenyx reported a net loss of  million or  per share basic and diluted compared with a net loss of  million or  per share basic and diluted in the second quarter of  for the six months ended june   net loss was  million or  per share basic and diluted compared with a net loss for the same period in  of  million or  per share basic and diluted this reflected cash used in operations of  million for the six months ended june   compared to  million for the same period in  total operating expenses for the second quarter of  were  million compared with  million for the same period in  including noncash stockbased compensation of  million and  million for the second quarter of  and  respectively total operating expenses for the six months ended june   were  million compared with  million for the same period in  including noncash stockbased compensation of  million and  million in the first six months of  and  respectively the increase in total operating expenses is due to the increase in development commercial and general and administrative costs as the company grows and advances its pipeline cash cash equivalents and investments were  million as of june   recent highlights burosumab krn antifgf monoclonal antibody in xlinked hypophosphatemia xlh submission of a us bla for burosumab for the treatment of pediatric and adult xlh patients planned in august  in june  we announced that we had reached agreement with the fda at a prebiologics license application prebla meeting on the clinical package to support the burosumab bla filing for xlh at the meeting the fda agreed that the bla could be submitted based on available clinical data and confirmed that both pediatric and adult indications would be included in the review specifically for pediatric patients the filing will include the week data from our phase  study in  year olds and week data from the phase  study in  year olds the fda confirmed that data from the ongoing pediatric phase  study would not be required for the bla filing to support the adult indication the submission will include the week placebocontrolled data from the adult phase  study additionally fda agreed to accept any available bone biopsy data from the week open label bone quality study in adults as supportive evidence two new pieces of data on adult patients to be included in the burosumab bla bone biopsy results from the first two adults in the bone quality study will be included in the burosumab bla in this study baseline biopsies obtained from  patients confirmed that a majority of the patients had severe osteomalacia with a mean osteoid volumebone volume of  vs normal range of  these data verify that adult xlh patients have severe underlying bone disease even many years past puberty followup biopsies after  weeks of burosumab treatment are available from the first two patients for these two patients osteoid volumebone volume was decreased from  and  to  and  respectively osteomalacia was characterized by the pathologist as improving from severe to mild disease additionally a posthoc statistical analysis of bone fracture healing in the recently announced adult phase  placebocontrolled study showed an odds ratio of  for complete healing of fractures and pseudofractures in the burosumab group compared to the placebo group p at  weeks burosumab designated a drug for a “rare pediatric disease” the fda’s office of orphan drug development oopd has recently designated burosumab for the treatment of xlh as a drug for a “rare pediatric disease” under fdas rare pediatric disease priority review voucher program companies who receive approval for a new drug application or bla for a rare pediatric disease may be eligible to receive a voucher for a priority review of a subsequent marketing application for a different product the priority review voucher may be used by the company or sold to a third party european conditional marketing authorization application maa to be focused on pediatric indication to ensure the expeditious availability of burosumab for pediatric xlh patients in europe and to avoid any potential delays in the review procedure due to the large amount of recent data from the adult xlh phase  study to be filed our partners kyowa hakko kirin co ltd kyowa hakko kirin and kyowa kirin international plc have decided to separate the adult and pediatric indications a filing for the adult indication is planned after a decision is first reached on the pediatric indication turkey agreement with kyowa kirin in may  ultragenyx signed an agreement with a wholly owned subsidiary of kyowa kirin pursuant to which ultragenyx was granted the right to commercialize burosumab in turkey this subsidiary will have the option to take over commercialization efforts after a certain minimum period vestronidase alpha or rhgus in mucopolysaccharidosis  mps  bla and maa filings accepted for review the fda has granted vestronidase alpha priority review status and the bla has a pdufa goal date for a decision of november   the committee for medicinal products for human use chmp opinion is expected in the first half of  upcoming key milestones burosumab in xlh ultragenyx plans to submit a bla for both adult and pediatric patients to the us fda for burosumab in august    based on followup discussions with the fda on the content and structure of the filing the bla filing is in final assembly and will be submitted in august given that the product is designated as a breakthrough therapy it is expected that burosumab would obtain priority review after the filing which would indicate an month review period opinion from chmp on the burosumab conditional maa for pediatric xlh expected around the end of  the maa was submitted and accepted for review by the european medicines agency ema in december  vestronidase alpha in mps  pdufa goal date and chmp opinion the pdufa goal date for a decision is november   and no advisory committee meeting is expected in the us at this time the chmp opinion is expected in the first half of  aceneuramic acid extended release aceer in gne myopathy data from the pivotal phase  study in gne myopathy expected in the second half of  the fully enrolled randomized doubleblind placebocontrolled international study in  patients is evaluating the efficacy and safety of aceer compared with placebo over  weeks we plan to submit an nda and maa based on the phase  data if positive  ux in longchain fatty acid oxidation disorders lcfaod and glut deficiency syndrome glut ds phase  study in faod patients we continue to plan for discussions with regulators regarding the phase  study in faod patients  phase  movement disorder study in glut ds patients ongoing the randomized doubleblind placebocontrolled crossover study is enrolling approximately  patients the primary endpoint compares the frequency of disabling paroxysmal movement disorder events with ux to placebo as recorded by a daily electronic diary conference call  webcast information ultragenyx will host a conference call today thursday july   at pm et to discuss second quarter  financial results and to provide a corporate update the live and replayed webcast of the call will be available through the company’s website at httpirultragenyxcomeventscfm to participate in the live call by phone dial  usa or  international and enter the passcode  the replay of the call will be available for one year about ultragenyx ultragenyx is a clinicalstage biopharmaceutical company committed to bringing to market novel products for the treatment of rare and ultrarare diseases with a focus on serious debilitating genetic diseases founded in  the company has rapidly built a diverse portfolio of product candidates with the potential to address diseases for which the unmet medical need is high the biology for treatment is clear and for which there are no approved therapies the company is led by a management team experienced in the development and commercialization of rare disease therapeutics ultragenyx’s strategy is predicated upon time and costefficient drug development with the goal of delivering safe and effective therapies to patients with the utmost urgency for more information on ultragenyx please visit the company’s website at wwwultragenyxcom ultragenyx product candidates ultragenyx has completed a phase  study of vestronidase alpha rhgus in patients with mucopolysaccharidosis  mps  a rare lysosomal storage disease and is conducting a phase  study of aceneuramic acid extendedrelease aceer in patients with gne myopathy a progressive musclewasting disorder phase  and phase  studies of burosumab an antibody targeting fibroblast growth factor  fgf in pediatric and adult patients with xlinked hypophosphatemia xlh and a phase  study in tumor induced osteomalacia tio both rare diseases that impair bone mineralization a phase  study for ux in patients with glucose transporter type deficiency syndrome glut ds a brain energy deficiency who are experiencing movement disorders a phase  study of ux in glut ds patients with seizures and a phase  clinical study of ux in patients severely affected by longchain fatty acid oxidation disorders lcfaod a genetic disorder in which the body is unable to convert long chain fatty acids into energy forwardlooking statements except for the historical information contained herein the matters set forth in this press release including statements regarding ultragenyxs expectations regarding the timing of release demonstrated impact and adequacy of clinical data and other information to support approval of product candidates its intent to make regulatory submissions and its expectations regarding timing of receiving potential approval of its product candidates ongoing or additional studies for its product candidates and timing regarding these studies the design of clinical studies the extent of its translational research program potential indications for its product candidates discussions with regulatory authorities and sufficiency for and timing of regulatory submissions are forwardlooking statements within the meaning of the safe harbor provisions of the private securities litigation reform act of  such forwardlooking statements involve substantial risks and uncertainties that could cause our clinical development programs future results performance or achievements to differ significantly from those expressed or implied by the forwardlooking statements such risks and uncertainties include among others the uncertainties inherent in the clinical drug development process such as the regulatory approval process the timing of our regulatory filings and other matters that could affect sufficiency of existing cash cash equivalents and shortterm investments to fund operations and the availability or commercial potential of our drug candidates ultragenyx undertakes no obligation to update or revise any forwardlooking statements for a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forwardlooking statements as well as risks relating to the business of the company in general see ultragenyxs quarterly report on form q filed with the securities and exchange commission on may   and its subsequent periodic reports filed with the securities and exchange commission                       ultragenyx pharmaceutical inc     selected statement of operations financial data     in thousands except share and per share amounts     unaudited                           three months ended june     six months ended june                                       statement of operations data                   revenue                           operating expenses                   research and development                               general and administrative                               total operating expenses                               loss from operations                           other income net                               loss before income taxes                           income tax provision                             net loss                       net loss per share basic and diluted                       shares used in computing net loss per share                   basic and diluted                                             ultragenyx pharmaceutical inc     selected balance sheets financial data     in thousands     unaudited         june    december                      balance sheet data             cash cash equivalents and investments             working capital               total assets               total stockholders equity               contact ultragenyx pharmaceutical inc investors  media ryan martins  follow this company no thanks continue reading get free realtime alerts now or use social media sign in with facebook  we hate spam and so do you we wont ever share your email address or send you unsolicited mail ultragenyx pharmaceutical inc nasdaqrare healthcare  medical services           contact information ultragenyx pharmaceutical inc  leveroni court novato ca usa  p    related articles related media related links alert types messages notifications